Digital Biomanufacturing Market 2025

Digital Biomanufacturing Market Size

The global digital biomanufacturing market reached a value of nearly $21,106.79 million in 2024, having grown at a compound annual growth rate (CAGR) of 11.49% since 2019. The market is expected to grow from $21,106.79 million in 2024 to $40,269.78 million in 2029 at a rate of 13.79%. The market is then expected to grow at a CAGR of 13.78% from 2029 and reach $76,784.37 million in 2034. Growth in the historic period resulted from the shift towards personalized medicine, expansion of the pharmaceutical industry, rising demand for biologics and growth in contract development and manufacturing organizations (CDMOs). Factors that negatively affected growth in the historic period were cybersecurity and data integrity concerns and limited awareness in developing countries. Going forward, increasing prevalence of chronic disease, expansions of biopharmaceutical plants, rise in biosimilars production and rise in use of artificial intelligence and machine learning in healthcare will drive the growth. Factors that could hinder the growth of the digital biomanufacturing market in the future include high initial capital investment, lack of knowledge in meditech innovation and impact of trade war and tariff.

Digital Biomanufacturing Market Drivers

The key drivers of the digital biomanufacturing market include: Increasing Prevalence Of Chronic Disease During the forecast period, a growing number of chronic diseases like cancer, diabetes and autoimmune disorders will drive the growth in the digital biomanufacturing market. As more people are diagnosed with these conditions, the need for biologic therapies rises. These therapies depend on advanced digital manufacturing solutions to produce high-quality treatment quickly and cost-effectively. Digitalization allows manufacturers to swiftly respond to changes in healthcare needs and regulatory rules, making it easier to develop and deliver new treatments on time. This trend supports the growth of digital biomanufacturing, strengthens the industry's ability to solve complex medical challenges and ultimately leads to better patient outcomes and faster market growth. Hence the rise in chronic diseases is significantly influencing the digital biomanufacturing market, driving the need for innovative and efficient biologic therapies. The increasing prevalence of chronic disease growth contribution during the forecast period in 2024 is 2.00%.

Digital Biomanufacturing Market Restraints

The key restraints on the digital biomanufacturing market include: High Initial Capital Investment During the forecast period, the high initial capital investment is expected to restrain the growth of the digital biomanufacturing market. The considerable initial expenses involved in adopting digital biomanufacturing solutions create a significant obstacle to market expansion. The required investments in automation, advanced data analysis and digital infrastructure can be quite high, making it difficult for smaller businesses or organizations with limited financial resources. As a result, this financial challenge may deter many potential users from adopting digital technologies, which can slow down the overall digital transformation process within the biomanufacturing industry. Consequently, the wider market may face slow growth, with only larger or well-capitalized companies able to fully leverage the advantages of digital biomanufacturing in the short term. Therefore, the high initial capital investment required for digital biomanufacturing poses a significant barrier in the market. Growth affected by high initial capital investment during the forecast period in 2024 is -2.00%.

Digital Biomanufacturing Market Trends

Major trends shaping the digital biomanufacturing market include: Adoption Of AI And Automation For Smarter Bioprocessing Companies in digital biomanufacturing are increasingly adopting artificial intelligence (AI) and machine learning (ML) to improve efficiency, automate key processes and ensure consistent product quality. These tools analyze real-time and historical process data to predict deviations, adjust parameters such as pH and temperature and reduce variability, resulting in faster, more reliable and cost-effective production. For instance, in April 2025, Sartorius Stedim Biotech, a France-based biomanufacturing solutions provider, announced a strategic partnership with Tulip Interfaces, a U.S.-based leader in no-code operations platforms. The partnership focuses on enhancing end-to-end visibility and optimization in single use bioprocessing by integrating Sartorius’s bioprocessing systems with Tulip’s real-time digital platform. This collaboration enables smarter process control, reduces manual errors and improves data accessibility across production teams, highlighting how AI and automation are transforming digital biomanufacturing. Focus On Expansion Of AI-Enabled Biomanufacturing Facilities To Strengthen Healthcare Resilience Major companies in the digital biomanufacturing market are focusing on expanding and developing innovative production facilities. These companies are expanding smart, AI-enabled production facilities aimed at enhancing biologics manufacturing capabilities and national healthcare resilience. Such advancements not only accelerate production timelines but also support consistent product quality and compliance with regulatory standards. For instance, In May 2024, Sanofi, a France-based AI-powered biopharma company involved in digital biomanufacturing, announced an investment of over €1 billion ($1.08 billion) to expand its biomanufacturing facilities in France, building on the €2.5 billion ($2.70 billion) it has already allocated to major initiatives in the country. This latest investment will generate more than 500 new jobs and bolster France’s capacity to independently produce vital medicines and vaccines, reinforcing its health sovereignty. The funding targets three key sites, Vitry-sur-Seine, Le Trait and Lyon Gerland, where Sanofi will scale up production of critical biologic therapies for conditions such as Chronic Obstructive Pulmonary Disease (COPD), asthma, multiple sclerosis and type 1 diabetes.

Opportunities And Recommendations In The Digital Biomanufacturing Market

Opportunities – The top opportunities in the digital biomanufacturing markets segmented by type will arise in the manufacturing technologies segment, which will gain $9,095.49 million of global annual sales by 2029. The top opportunities in the digital biomanufacturing markets segmented by types of biologic(s) manufactured will arise in the antibodies segment, which will gain $9,530.55 million of global annual sales by 2029. The top opportunities in the digital biomanufacturing markets segmented by technology will arise in the AI and IoMT solutions segment, which will gain $5,928.16 million of global annual sales by 2029. The top opportunities in the digital biomanufacturing markets segmented by application will arise in the biomanufacturing process automation and control segment, which will gain $9,580.33 million of global annual sales by 2029. The top opportunities in the digital biomanufacturing markets segmented by end user will arise in the biopharmaceutical companies’ segment, which will gain $15,001.26 million of global annual sales by 2029. The digital biomanufacturing market size will gain the most in the USA at $6,054.18 million. Recommendations- To take advantage of the opportunities, The Business Research Company recommends the digital biomanufacturing companies to focus on integrating AI and ML for smarter bioprocess control, focus on integrating sensor systems for real-time bioprocess optimization, focus on adopting cloud platforms for scalable and remote biomanufacturing, focus on manufacturing technologies to maximize growth opportunities, focus on cell and gene therapies to capture high-growth potential, focus on predictive analytics and digital twin technologies to lead innovation, expand in emerging markets, focus on expanding AI-enabled facilities to strengthen biologics manufacturing, provide competitively priced offerings, focus on outcome-based pricing to reflect process efficiency gains, continue to use B2B promotions, focus on data-driven promotion to engage decision-makers and demonstrate value and focus on biomanufacturing process automation and control to maximize scalability.